Introduction and Objective: Antidiabetic agents differ in their mechanisms of action and can exert distinct long-term effects on β-cell function (BCF). Hyperglycemic clamp studies (HC) enable detailed assessment of first- and second-phase insulin secretion (ISecr), yet comparative longitudinal data across drug classes among individuals with PreDM remains limited.Methods: Sixty PreDM subjects were studied and treated […]
Read MoreMonth: June 2026
1364-P: Exercise with PACTAID Maintains Time in Range and Reduces Hypoglycemia in Adults with Type 1 Diabetes Using Automated Insulin Delivery
by sugaradmin
Introduction and Objective: To evaluate the feasibility and effectiveness of the PACTAID application in reducing hypoglycemia during and after exercise in adults with type 1 diabetes (T1D) using the Tandem Control-IQ system.Methods: In this prospective study, adults with T1D on Control-IQ completed 20 exercise sessions with PACTAID support. Baseline and end-of-study assessments included ambulatory blood […]
Read More1036-OR: ADA Presidents' Select Abstract: Food Insecurity and Level 3 Hypoglycemia in Non-Insulin-Treated Secretagogue Users (iNPHORM, USA)
by sugaradmin
Introduction and Objective: Food insecurity is a key risk factor for severe hypoglycemia among insulin users. Whether this extends to non-insulin-treated secretagogue users remains unexamined, despite widespread prescribing of these agents, particularly in cost-sensitive contexts. We analyzed data from the iNPHORM study to address this gap.Methods: Adults (≥18 years) with type 2 diabetes (T2D) on […]
Read More2978-LB: Annual Prevalence of Diabetic Ketoacidosis and Severe Hypoglycemia in Type 2 Diabetes
by sugaradmin
Introduction and Objective: Diabetic ketoacidosis (DKA) and severe hypoglycemia (SH) require costly, high-intensity acute care. Recent trends in type 2 diabetes (T2D) are not well described. We estimated annual prevalence of DKA and SH requiring emergency department (ED) or inpatient (IP) care among people with T2D.Methods: We analyzed Inovalon Insights claims (2017-2024) from Commercial, Managed […]
Read More2346-P: Access to GLP-1 Receptor Agonists (GLP-1RA) and Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) for Type 2 Diabetes Mellitus (T2DM) by Sociodemographic Factors in a Large Integrated Health System
by sugaradmin
Introduction and Objective: GLP-1 RAs and SGLT-2i have transformed T2DM management by improving glycemic control, promoting weight loss, and reducing the risk of cardiometabolic-renal disease. This study’s aim was to assess real world prescribing patterns of GLP-1 RAs and SGLT-2i within a large health care system and assess variations across sociodemographic groups.Methods: A retrospective analysis […]
Read More2351-P: Assessment of Phenotypic Clustering of Incident and Prevalent Type 2 Diabetes: A MESA Pilot Study in the Definition, Etiology, Function: Integration to Enhance Type 2 Diabetes Treatment (DEFINE-Type 2 Diabetes) Consortium
by sugaradmin
Introduction and Objective: Phenotypic clustering of T2D into aging-related (MARD), obesity-related (MOD), insulin-deficient (SIDD), and insulin-resistant (SIRD) subgroups may capture heterogeneity, but performance and stability in diverse populations are uncertain.Methods: We performed established k-means clustering models in 871 prevalent and 462 incident T2D cases with data for age at onset, BMI, HbA1c, HOMA2-IR, and HOMA2-β […]
Read More2110-P: Risk Factors for Elevated Blood Pressure in Children with Type 1 Diabetes: Evidence from a Population-Based EHR Cohort and a Pediatric Biobank
by sugaradmin
Introduction and Objective: Elevated blood pressure (BP) is a common but underrecognized contributor to vascular complications in children with type 1 diabetes (T1D). We aimed to characterize BP patterns and kidney function trajectories in pediatric T1D and to identify clinical, immune, and genetic predictors of elevated BP.Methods: We examined longitudinal patterns of BP and eGFR […]
Read More2614-P: Understanding the Lived Experiences of Dosing Practices among People Living with Obesity (PwO) Using Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) for Weight Loss (WL): A U.S. Qualitative Study
by sugaradmin
Introduction and Objective: GLP-1 RAs are increasingly used for WL, yet little is known about how PwO experience and personalize treatment in everyday life. This mixed-method study aimed to elucidate the dynamics shaping treatment experiences and dosing practices of PwO using GLP-1 RA in the US.Methods: Public user-generated content from Reddit (N>250,000 posts) and YouTube […]
Read More2609-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1 Receptor Agonist HDM1002 in Chinese Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
by sugaradmin
Introduction and Objective: HDM1002, a novel, orally bioavailable non-peptide full agonist of GLP-1RA, demonstrated promising weight loss in phase 1 trial. This phase 2 study evaluated the efficacy and safety of HDM1002 in Chinese overweight and obese adults without diabetes mellitus.Methods: In this randomized, double-blind, placebo-controlled, multicenter study (NCT06500299), 185 participants (pts) (BMI 28-40 kg/m²) […]
Read More49-PUB: Targeting Hepatic Oxidative Stress in Diabetes: Antioxidant and Cytoprotective Effects of Hypericum perforatum L. Aerial and Hairy Root Methanolic Extracts
by sugaradmin
Introduction and Objective: Diabetes mellitus is associated with pronounced hepatic oxidative stress caused by excessive reactive oxygen species production, impaired antioxidant defenses, and activation of stress-responsive signaling pathways. Building on evidence of the antidiabetic potential of Hypericum perforatum L. aerial parts (Hyperici herba, HH) and H. perforatum hairy root (HR) extracts, this study aimed to […]
Read More